Newly Developing IgM Anti-GD1a/GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Ruby F Ross, Jennifer A Langsdorf, Norman Latov
✦ AI-curated · Sources linked
Case in brief
A patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) presented with an atypical development of IgM monoclonal gammopathy and positive anti-ganglioside antibodies after 20 years of disease. This finding prompted a reassessment of his treatment strategy due to clinical worsening while on maintenance therapy.
What made this case unusual
The emergence of IgM monoclonal gammopathy and anti-ganglioside antibodies in a long-standing case of CIDP is noteworthy, highlighting a potential progression in the disease's immunological profile.
Diagnostic / clinical pearl
Clinicians should consider testing for anti-ganglioside antibodies and monoclonal gammopathies in CIDP patients who experience clinical deterioration despite ongoing treatment.
Why it matters
This case underscores the importance of monitoring for evolving immunological changes in chronic conditions like CIDP, which may necessitate adjustments in management.